# Clinical Trial Landscape: 01_nsclc_kras_g12c_standard

*Generated: 2026-01-05 18:27:00*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 12

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 1 | 27 | █████ 27.0% |
| Phase 1/Phase 2 | 24 | ████ 24.0% |
| Phase 2 | 22 | ████ 22.0% |
| Phase 3 | 13 | ██ 13.0% |
| Unknown | 7 | █ 7.0% |
| Phase 2/Phase 3 | 5 | █ 5.0% |
| Not Applicable | 2 |  2.0% |

## Status Distribution

- **Recruiting**: 97 (97.0%)
- **Not yet recruiting**: 3 (3.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| Merck Sharp & Dohme LLC | 7 |
| Hoffmann-La Roche | 4 |
| Mirati Therapeutics Inc. | 4 |
| Eli Lilly and Company | 4 |
| National Cancer Institute (NCI) | 3 |
| M.D. Anderson Cancer Center | 3 |
| Amgen | 3 |
| Revolution Medicines, Inc. | 3 |
| Bristol-Myers Squibb | 3 |
| Vanderbilt-Ingram Cancer Center | 2 |
| Daiichi Sankyo | 2 |
| SWOG Cancer Research Network | 2 |
| City of Hope Medical Center | 2 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Thera | 2 |
| Pfizer | 2 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Pembrolizumab | 26 |
| Carboplatin | 23 |
| Pemetrexed | 21 |
| Cisplatin | 16 |
| Cetuximab | 12 |
| Adagrasib | 11 |
| Paclitaxel | 9 |
| Sotorasib | 9 |
| Biospecimen Collection | 8 |
| Computed Tomography | 7 |
| Magnetic Resonance Imaging | 6 |
| Gemcitabine | 6 |
| Atezolizumab | 5 |
| Divarasib | 5 |
| Bevacizumab | 5 |
| MK-1084 | 5 |
| Placebo | 5 |
| Nab-paclitaxel | 4 |
| Oxaliplatin | 4 |
| Entrectinib | 3 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Spain | 41 |
| South Korea | 33 |
| Australia | 32 |
| Italy | 30 |
| France | 30 |
| Canada | 25 |
| Japan | 24 |
| Taiwan | 24 |
| Poland | 23 |
| Netherlands | 22 |
| Germany | 22 |
| United Kingdom | 22 |
| Belgium | 21 |
| China | 20 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12C | manual | 1.0 |
| KRASG12C | manual | 0.9 |
| KRAS-G12C | manual | 0.9 |
| NSCLC | manual | 1.0 |
| KRAS G12C NSCLC | manual | 1.0 |
| KRAS G12C non-small cell lung cancer | llm | 0.9 |
| KRAS G12C lung adenocarcinoma | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| lung adenocarcinoma | llm | 0.8 |
| KRAS p.G12C | llm | 0.9 |
| KRASp.G12C | llm | 0.8 |
| KRAS-p.G12C | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07288034](https://clinicaltrials.gov/study/NCT07288034) | Phase 2 | Not yet recruiting | City of Hope Medical... | Immunotherapy Biomarker Collection ... |
| [NCT07216404](https://clinicaltrials.gov/study/NCT07216404) | Phase 2 | Not yet recruiting | Alan Davis | Exploring the Safety, Acceptability... |
| [NCT07063745](https://clinicaltrials.gov/study/NCT07063745) | Phase 2/Phase 3 | Recruiting | Bristol-Myers Squibb | A Randomized Phase 2/3 Study of BMS... |
| [NCT07227025](https://clinicaltrials.gov/study/NCT07227025) | Phase 1/Phase 2 | Recruiting | Janssen Research & D... | A Phase 1/2 Study Evaluating the Sa... |
| [NCT06945484](https://clinicaltrials.gov/study/NCT06945484) | Not Applicable | Not yet recruiting | University of Utah | PILOT for The Precision Exercise Re... |
| [NCT07209111](https://clinicaltrials.gov/study/NCT07209111) | Phase 2 | Recruiting | Merck Sharp & Dohme ... | A Phase 2, Open-Label, Multicenter,... |
| [NCT07223047](https://clinicaltrials.gov/study/NCT07223047) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Open-Label, Multicent... |
| [NCT07223424](https://clinicaltrials.gov/study/NCT07223424) | Phase 2 | Recruiting | Diwakar Davar | Patient Preference for Subcutaneous... |
| [NCT06793215](https://clinicaltrials.gov/study/NCT06793215) | Phase 3 | Recruiting | Hoffmann-La Roche | A Phase III, Randomized, Open-Label... |
| [NCT07190248](https://clinicaltrials.gov/study/NCT07190248) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Open-label, ... |
| [NCT07090499](https://clinicaltrials.gov/study/NCT07090499) | Phase 1 | Recruiting | Pfizer | A Phase 1 Open-label Study to Inves... |
| [NCT07094204](https://clinicaltrials.gov/study/NCT07094204) | Phase 1 | Recruiting | Astellas Pharma Inc | A Phase 1 Study of ASP5834 in Parti... |
| [NCT06997497](https://clinicaltrials.gov/study/NCT06997497) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Open-label, ... |
| [NCT06907615](https://clinicaltrials.gov/study/NCT06907615) | Phase 2 | Recruiting | Shanghai Henlius Bio... | An Open-label, Multi-center, Global... |
| [NCT07023731](https://clinicaltrials.gov/study/NCT07023731) | Phase 1/Phase 2 | Recruiting | Arvinas Inc. | A Phase 1/2 Clinical Trial to Evalu... |
| [NCT06881784](https://clinicaltrials.gov/study/NCT06881784) | Phase 3 | Recruiting | Revolution Medicines... | RASolve 301: Phase 3 Multicenter, O... |
| [NCT06975293](https://clinicaltrials.gov/study/NCT06975293) | Phase 1/Phase 2 | Recruiting | STORM Therapeutics L... | Open-label, Non-randomized, Multi-c... |
| [NCT06875310](https://clinicaltrials.gov/study/NCT06875310) | Phase 3 | Recruiting | Mirati Therapeutics ... | A Randomized, Double-Blind, Phase 3... |
| [NCT06917079](https://clinicaltrials.gov/study/NCT06917079) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06890598](https://clinicaltrials.gov/study/NCT06890598) | Phase 3 | Recruiting | Eli Lilly and Compan... | A Phase 3, Multicenter, Double-Blin... |
| [NCT06788912](https://clinicaltrials.gov/study/NCT06788912) | Phase 2 | Recruiting | Merck Sharp & Dohme ... | KEYMAKER-U01 Substudy 01E: A Phase ... |
| [NCT06804824](https://clinicaltrials.gov/study/NCT06804824) | Phase 1 | Recruiting | Vividion Therapeutic... | A Phase 1/1b, Open-Label, Multicent... |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Multicenter, Open-lab... |
| [NCT06720987](https://clinicaltrials.gov/study/NCT06720987) | Phase 1 | Recruiting | Kumquat Biosciences ... | A Phase 1/1b, Open-label, Multicent... |
| [NCT06807619](https://clinicaltrials.gov/study/NCT06807619) | Phase 1 | Recruiting | Memorial Sloan Kette... | BrainMet ADePPT (Anticancer Drug Pe... |
| [NCT06706076](https://clinicaltrials.gov/study/NCT06706076) | Phase 1/Phase 2 | Recruiting | BlossomHill Therapeu... | A Phase 1/2 Open-Label, Multicenter... |
| [NCT06712316](https://clinicaltrials.gov/study/NCT06712316) | Phase 2/Phase 3 | Recruiting | BioNTech SE | A Phase II/III, Multisite, Randomiz... |
| [NCT06667076](https://clinicaltrials.gov/study/NCT06667076) | Phase 2 | Recruiting | Janssen Research & D... | A Phase 2b, Open-Label, Two-cohort ... |
| [NCT06660407](https://clinicaltrials.gov/study/NCT06660407) | Phase 2 | Recruiting | Mayo Clinic | Grid Radiotherapy for Advanced Non-... |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Phase 1 | Recruiting | Zymeworks BC Inc. | A Phase 1, Open-label, Multicenter ... |
| [NCT06644768](https://clinicaltrials.gov/study/NCT06644768) | Phase 1/Phase 2 | Recruiting | Daiichi Sankyo | A Multicenter, Randomized, Open-Lab... |
| [NCT06607185](https://clinicaltrials.gov/study/NCT06607185) | Phase 1 | Recruiting | Eli Lilly and Compan... | A Phase 1a/1b Study of the Pan-KRAS... |
| [NCT06562192](https://clinicaltrials.gov/study/NCT06562192) | Phase 1 | Recruiting | Novartis Pharmaceuti... | Phase I Open-label, Multi-center St... |
| [NCT06333951](https://clinicaltrials.gov/study/NCT06333951) | Phase 1 | Recruiting | Amgen | A Phase 1b Study Evaluating the Saf... |
| [NCT06582771](https://clinicaltrials.gov/study/NCT06582771) | Phase 2 | Recruiting | Memorial Sloan Kette... | A Phase 2 Study of First-line Sotor... |
| [NCT06412198](https://clinicaltrials.gov/study/NCT06412198) | Phase 1/Phase 2 | Recruiting | M.D. Anderson Cancer... | A Multicenter Phase 1b/2 Study of A... |
| [NCT06452277](https://clinicaltrials.gov/study/NCT06452277) | Phase 3 | Recruiting | Bayer | A Phase 3 Open-label, Randomized, A... |
| [NCT06162572](https://clinicaltrials.gov/study/NCT06162572) | Phase 1/Phase 2 | Recruiting | Servier Bio-Innovati... | A Phase 1b/2, Multicenter, Open-lab... |
| [NCT06248606](https://clinicaltrials.gov/study/NCT06248606) | Phase 2 | Recruiting | Ryan Gentzler, MD | Phase II Study of Adagrasib + Stere... |
| [NCT05638295](https://clinicaltrials.gov/study/NCT05638295) | Phase 2 | Recruiting | National Cancer Inst... | A Randomized Phase II Study of AMG ... |
| [NCT06252649](https://clinicaltrials.gov/study/NCT06252649) | Phase 3 | Recruiting | Amgen | Phase 3 Multicenter, Randomized, Op... |
| [NCT06475807](https://clinicaltrials.gov/study/NCT06475807) | Not Applicable | Recruiting | University of Pittsb... | Cancer Nutrition Study: CaNS - A Pi... |
| [NCT06447662](https://clinicaltrials.gov/study/NCT06447662) | Phase 1 | Recruiting | Pfizer | A Phase 1 Open-Label Study of PF-07... |
| [NCT06345729](https://clinicaltrials.gov/study/NCT06345729) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Double-blind... |
| [NCT06343402](https://clinicaltrials.gov/study/NCT06343402) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06262321](https://clinicaltrials.gov/study/NCT06262321) | Phase 2 | Recruiting | University of Roches... | Phase II Trial of Thoracic Radiothe... |
| [NCT06249282](https://clinicaltrials.gov/study/NCT06249282) | Phase 1 | Recruiting | City of Hope Medical... | A Phase I Clinical Trial of Carfilz... |
| [NCT06150664](https://clinicaltrials.gov/study/NCT06150664) | Phase 1 | Recruiting | Compass Therapeutics | A Phase 1, Open-Label, Multiple-Asc... |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Phase 2 | Recruiting | Mirati Therapeutics ... | A Randomized Study of Two Dosing Re... |
| [NCT06244771](https://clinicaltrials.gov/study/NCT06244771) | Phase 1/Phase 2 | Recruiting | Frontier Medicines C... | An Open-Label, Phase 1/2 Dose Escal... |

*... and 50 more trials (see trials.csv for full list)*
